Voyager Therapeutics (NASDAQ:VYGR) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Voyager Therapeutics (NASDAQ:VYGR) announced its quarterly earnings data on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.08, Zacks reports. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%.

Voyager Therapeutics Trading Up 1.0%

Shares of Voyager Therapeutics stock traded up $0.03 during trading hours on Thursday, reaching $3.13. The stock had a trading volume of 421,035 shares, compared to its average volume of 646,793. The firm has a 50 day simple moving average of $3.42 and a two-hundred day simple moving average of $3.74. The firm has a market capitalization of $189.11 million, a price-to-earnings ratio of -1.59 and a beta of 1.31. Voyager Therapeutics has a 1 year low of $2.93 and a 1 year high of $5.55.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a report on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Finally, Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Institutional Trading of Voyager Therapeutics

A number of institutional investors have recently modified their holdings of VYGR. Wexford Capital LP acquired a new stake in Voyager Therapeutics during the 3rd quarter worth approximately $42,000. CIBC Asset Management Inc acquired a new position in Voyager Therapeutics during the fourth quarter valued at approximately $45,000. Coldstream Capital Management Inc. purchased a new stake in Voyager Therapeutics during the third quarter worth approximately $55,000. Virtu Financial LLC purchased a new stake in Voyager Therapeutics during the third quarter worth approximately $93,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of Voyager Therapeutics in the second quarter worth $78,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.